Join us at the 2015 BIO International Convention

June 9, 2015

We see opportunities for transforming medicines where others cannot because of our proprietary technologies, as well as our employees’ expertise and experience in R&D, manufacturing complex products and commercialization.

 

On April 1, 2015, Aptalis Pharmaceutical Technologies was divested from Actavis plc (NYSE: ACT) to TPG, a global private investment firm. The company’s new name is Adare Pharmaceuticals.

 

Adare Pharmaceuticals provides enhanced medicines, creating new possibilities for improved patient health.

 

For decades, we have solved complex formulation, manufacturing and commercialization challenges, resulting in transformational medicines that deliver value to all our stakeholders.

 

We see opportunities for transforming medicines where others cannot because of our proprietary technologies, as well as our
employees’ expertise and experience in R&D, manufacturing complex products and commercialization.

 

For more information on Adare, join us at the 2015 BIO International Convention for a capabilities presentation by Anthony Recupero, PhD, on June 16, 2015, at 4:15 PM in Theater 2, “The Gene Lantern.”

 

To learn more about our proprietary technologies or opportunities for product out-licensing, schedule a meeting through the BIO One-on-One Partnering System to meet with us at BIO International in Philadelphia, PA, June15-18, 2015.

 

If you are unable to attend BIO and would like to learn more about Adare, please contact Lisa.Miller@adarepharma.com or visit www.AdarePharma.com.

 

©2015 Adare Pharmaceuticals, Inc.